Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

NCT02406833 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma

Interventions

DRUG: TGF-β2 antisense oligonucleotide
PROCEDURE: Trabeculectomy

Sponsor

Isarna Therapeutics GmbH